A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Trial details
- Registry ID
- NCT04625270
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as avutometinib (VS-6766) and VS-6063
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationNCT04625270 | VSTM | Phase 2 | Active not recruiting | 2024-11-15Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |